Emyria agrees licensing and commercialisation deal for EMD-RX5

Emyria Ltd (ASX:EMD) MD Michael Winlo tells Proactive the company has signed a deal with Aspen Pharmacare (JSE:APN) Australia for the licensing and commercialisation of EMD-RX5. The agreement supports the registration and commercialisation of EMD-RX5 as an over-the-counter (OTC) treatment in Australia.

Proactive Investors

Jonathan Jackson

+61 413 713 744

Jonathan@proactiveinvestors.com